A recent prospective, observational study investigated the use of direct oral anticoagulants for use in patients with postoperative atrial fibrillation and found favorable safety and efficacy results.
A recent prospective, observational study looked to investigate the use of direct oral anticoagulants (DOACs) for use in patients with postoperative atrial fibrillation (POAF).
POAF, the most common complication after cardiac surgery, has an incidence of 16% to 85%. Stroke is the most important clinical outcome of POAF and significantly affects the prognosis of the patient. The authors noted that at their medical facility, 24% of the 761 patients who underwent isolated coronary artery bypass grafting experienced POAF, and 1.4% of these patients also experienced a stroke. Although anticoagulation therapy consisting of heparin and warfarin was administered shortly after POAF, stroke still occurred in 1.4% of patients. This led the authors to administer DOAC immediately after the occurrence of POAF in patients after undergoing cardiac surgery.
The study looked at data from 135 total patients who were classified into 3 drug treatment groups: apixaban (n = 31), edoxaban (n = 87), and rivaroxaban (n = 17). Primary end points were either bleeding or thromboembolic events. Secondary end points were changes in hemoglobin prothrombin time, activated partial thromboplastin time, serum creatinine, estimated glomerular filtration rate, and pleural/pericardial effusion.
Despite no significant differences observed in age, sex, body weight, creatinine clearance, basic disease, risk factors, and presurgical anticoagulation therapy, the onset of POAF was similar across the 3 treatment groups. Although no hospital deaths occurred, the total number of events was significantly higher in the rivaroxaban group (P = .007).
In terms of primary end points, gastrointestinal (GI) bleeding was observed in 3% (n = 1), 1% (n = 1), and 12% (n = 2) of the apixaban, edoxaban, and rivaroxaban groups, respectively. Pleural bleeding was seen in 6% of patients in the rivaroxaban group (n = 1). Major bleeding and GI bleeding were more common in the rivaroxaban group (major bleeding: P = .011; GI bleeding: P = .047).
Analysis of the secondary end points found that in all 3 groups, there were no significant changes in hemoglobin from pretreatment to post DOAC treatment (P = .543), but hemoglobin did increase 1 month after administration of DOAC treatment (P < .0001) in each group. Prothrombin time was significantly more prolonged in apixaban than edoxaban at week 1 and month 1 (one week: P = .017; one month: P = .012). Similarly, activated partial thromboplastin time was more prolonged in the apixaban group than the rivaroxaban group (P = .011). In terms of pleural and pericardial infusion, there were no statistically significant differences across treatment groups (P = .840). Differences in serum creatinine and creatinine clearance were also not statistically significant. Notably, stroke was observed in 1 patient in the rivaroxaban group.
The authors found that the safety of DOACs was favorable, noting a low incidence of major bleeding. As there was only 1 case of stroke observed in the study, the authors wrote that “the efficacy of DOAC is excellent.” However, the authors also recommended that a future randomized, multicenter clinical trial should be conducted in order to further investigate the differences among DOACs.
Reference
Sezai A, Taoka M, Osaka S, et al. A comparative prospective observational study on the use of direct oral anticoagulants after cardiac surgery for the management of atrial fibrillation. Ann Thorac Cardiovasc Surg. Published online November 18, 2020. doi:10.5761/atcs.oa.20-00213
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
March 14th 2025Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Closing the Gaps in Cardiac Care With Technology, Collaboration
March 12th 2025Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Read More